Axsome Therapeutics Stock Alpha and Beta Analysis
| AXSM Stock | USD 98.22 1.43 1.44% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Axsome Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Axsome Therapeutics over a specified time horizon. Remember, high Axsome Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Axsome Therapeutics' market risk premium analysis include:
Beta 0.55 | Alpha 0.11 | Risk 2.51 | Sharpe Ratio 0.069 | Expected Return 0.17 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Axsome |
Axsome Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Axsome Therapeutics market risk premium is the additional return an investor will receive from holding Axsome Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Axsome Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Axsome Therapeutics' performance over market.| α | 0.11 | β | 0.55 |
Axsome Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Axsome Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Axsome Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Axsome Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Axsome Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Axsome Therapeutics shares will generate the highest return on investment. By understating and applying Axsome Therapeutics stock market price indicators, traders can identify Axsome Therapeutics position entry and exit signals to maximize returns.
Axsome Therapeutics Return and Market Media
The median price of Axsome Therapeutics for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 is 91.18 with a coefficient of variation of 4.18. The daily time series for the period is distributed with a sample standard deviation of 3.82, arithmetic mean of 91.57, and mean deviation of 2.96. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 11016 shares by Saad Mark E of Axsome Therapeutics at 3.67 subject to Rule 16b-3 | 09/11/2024 |
2 | Acquisition by Pizzie Nick of 36086 shares of Axsome Therapeutics at 65.02 subject to Rule 16b-3 | 10/04/2024 |
3 | Will Auvelity Sunosi Fuel Axsomes Growth Amid Stiff Competition | 10/11/2024 |
4 | Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts | 11/11/2024 |
5 | Axsome shares rise as Guggenheim lifts target to 135 | 11/12/2024 |
6 | Stocks Showing Rising Market Leadership Axsome Therapeutics Earns 82 RS Rating | 11/13/2024 |
7 | Fairmount Funds Management LLC Acquires Significant Stake in Astria Therapeutics Inc | 11/15/2024 |
8 | Disposition of 33410 shares by Coleman Mark of Axsome Therapeutics at 5.94 subject to Rule 16b-3 | 11/19/2024 |
9 | StockNews.com Upgrades Axsome Therapeutics to Hold | 11/21/2024 |
10 | Acquisition by Coleman Mark of 500 shares of Axsome Therapeutics at 58.15 subject to Rule 16b-3 | 11/22/2024 |
11 | Does Axsome Therapeutics Have A Healthy Balance Sheet | 11/25/2024 |
12 | Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 ... | 11/26/2024 |
13 | Axsome Therapeutics Research Analysts Recent Ratings Changes | 11/27/2024 |
About Axsome Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Axsome or other stocks. Alpha measures the amount that position in Axsome Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.64 | 0.67 | Days Of Inventory On Hand | 211.94 | 283.42 |
Axsome Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Axsome Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Axsome Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Axsome Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Axsome Therapeutics. Please utilize our Beneish M Score to check the likelihood of Axsome Therapeutics' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Axsome Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Axsome Therapeutics Backtesting, Axsome Therapeutics Valuation, Axsome Therapeutics Correlation, Axsome Therapeutics Hype Analysis, Axsome Therapeutics Volatility, Axsome Therapeutics History and analyze Axsome Therapeutics Performance. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Axsome Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.